Lazolvan Strawberry-Cream Flavored Syrup, 30 mg/5 mL, 100 mL per bottle.
Ingredients
Active ingredient: ambroxol hydrochloride;
5 mL of syrup contains 30 mg of ambroxol hydrochloride;
excipients: benzoic acid (E 210), hydroxyethylcellulose, sucralose, strawberry-cream flavor, vanilla flavor, purified water.
Dosage Form
Syrup.
Main physical and chemical properties: a clear or nearly clear, colorless or nearly colorless, slightly viscous liquid with a fruity strawberry-and-cream scent.
Pharmacotherapeutic group
Agents used for coughs and the common cold. Mucolytics. ATC code R05C B06.
Pharmacological Properties
Pharmacodynamics.
Preclinical studies have demonstrated that the active ingredient in Lazolvan® Strawberry-and-Cream-Flavored Syrup—ambroxol hydrochloride—increases the proportion of serous bronchial secretions. Ambroxol enhances the secretion of pulmonary surfactant by directly acting on type II pneumocytes in the alveoli and Clara cells in the bronchioles, and also stimulates ciliary activity, thereby reducing sputum viscosity and improving its clearance (mucociliary clearance). The improvement in mucociliary clearance has been demonstrated in clinical and pharmacological studies.
The activation of secretion, reduction in secretion viscosity, and improvement in mucociliary clearance promote mucus clearance and facilitate sputum expectoration.
In patients with COPD who received 75-mg extended-release ambroxol hydrochloride capsules for 6 months, a significant reduction in the number of exacerbations was observed compared with placebo by the end of the second month of treatment. In patients treated with ambroxol hydrochloride, the duration of illness was significantly shorter, and they required fewer days of antibiotic therapy. Compared with placebo, treatment with ambroxol hydrochloride extended-release capsules showed a statistically significant improvement in patients’ condition regarding sputum production, cough, shortness of breath, and auscultatory findings.
In a rabbit eye model, a local anesthetic effect of ambroxol hydrochloride was observed, which may be explained by its sodium channel-blocking properties. In vitro studies showed that ambroxol hydrochloride blocks voltage-gated neuronal sodium channels; the binding was reversible and concentration-dependent.
Ambroxol hydrochloride demonstrated anti-inflammatory effects in vitro. Thus, ambroxol hydrochloride significantly reduces the release of cytokines from mononuclear and polymorphonuclear cells in blood and tissues.
Clinical trials involving patients with pharyngitis demonstrated a significant reduction in throat pain and redness following treatment with ambroxol hydrochloride.
Due to the pharmacological properties of ambroxol, pain was rapidly relieved during the treatment of upper respiratory tract diseases, as observed in clinical efficacy studies of inhaled forms of ambroxol.
The use of ambroxol hydrochloride increases the concentrations of antibiotics (amoxicillin, cefuroxime, erythromycin, and doxycycline) in bronchopulmonary secretions and sputum. The clinical significance of this has not yet been established.
Pharmacokinetics.
Absorption. Absorption of ambroxol hydrochloride from immediate-release oral formulations is rapid and fairly complete, with a linear dose-response relationship within the therapeutic range. Maximum plasma levels are reached 1–2.5 hours after oral administration of immediate-release formulations and, on average, after 6.5 hours when using sustained-release formulations.
Distribution. Following oral administration, the distribution of ambroxol hydrochloride from the blood to tissues is rapid and extensive, with the highest concentration of the active ingredient found in the lungs. The volume of distribution after oral administration is 552 liters. In blood plasma within the therapeutic range, approximately 90% of the drug is bound to proteins.
Metabolism and Excretion. Approximately 30% of the dose is eliminated via presystemic metabolism following oral administration. Ambroxol hydrochloride is metabolized primarily in the liver by glucuronidation and cleavage to dibromantranilic acid (approximately 10% of the dose). Studies on human liver microsomes have shown that CYP3A4 is responsible for the metabolism of ambroxol hydrochloride to dibromantranilic acid.
Three days after oral administration, ambroxol hydrochloride is excreted in the urine, with about 6% of the dose excreted unchanged and approximately 26% of the dose excreted as conjugates of the compound.
The half-life of ambroxol hydrochloride is approximately 10 hours. Total clearance is approximately 660 mL/min, with renal clearance accounting for approximately 8% of total clearance. After 5 days, approximately 83% of the total dose is excreted in the urine.
Pharmacokinetics in Special Patient Populations. In patients with impaired liver function, the elimination of ambroxol hydrochloride is reduced, resulting in 1.3- to 2-fold higher plasma levels. Since the therapeutic range of ambroxol hydrochloride is sufficiently wide, no dosage adjustment is necessary.
Age and gender have no clinically significant effect on the pharmacokinetics of ambroxol hydrochloride; therefore, no dose adjustment is necessary.
Food intake does not affect the bioavailability of ambroxol hydrochloride.
Indications
Secretolytic therapy for acute and chronic bronchopulmonary diseases accompanied by impaired bronchial secretion and reduced mucus clearance.
Contraindications
Lazolvan® with strawberry-cream flavor, syrup, must not be used in patients with hypersensitivity to ambroxol hydrochloride or other components of the medication.
Lazolvan® Strawberry-Cream Flavored Syrup must not be administered to children under 2 years of age without a doctor’s prescription.
Interactions with Other Medications and Other Types of Interactions
Concomitant use of Lazolvan® strawberry-cream flavored syrup, 30 mg/5 mL, with cough suppressants may lead to excessive mucus accumulation due to suppression of the cough reflex. Therefore, such a combination is permissible only after a physician has carefully assessed the balance between the expected benefits and the potential risks of use.
Special Considerations for Use
There have been reports of severe skin reactions: erythema multiforme, Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN), and acute generalized exanthematous pustulosis (AGEP)—associated with the use of ambroxol hydrochloride. If signs of a worsening skin rash are present (sometimes associated with the appearance of blisters or mucosal involvement), treatment with ambroxol hydrochloride should be discontinued immediately and medical attention sought.
In cases of impaired bronchial motility and increased mucus secretion (for example, in a rare condition such as primary ciliary dyskinesia), Lazolvan® Strawberry-Cream Flavored Syrup should be used with caution due to the risk of promoting secretion accumulation.
Patients with impaired renal function or severe hepatic insufficiency should take Lazolvan® Strawberry-Cream Flavored Syrup only after consulting a doctor. In patients with severe renal insufficiency, the use of ambroxol—like any active ingredient that is metabolized in the liver and then excreted by the kidneys—may lead to the accumulation of metabolites formed in the liver.
Lasolvan® with strawberry-cream flavor, 30 mg/5 mL syrup, contains 1.2 g of sorbitol per 5 mL (equivalent to 4.9 g when taking the maximum recommended daily dose). Patients with rare hereditary fructose intolerance should not take this medication.
Use During Pregnancy or Breastfeeding
Pregnancy. Ambroxol hydrochloride crosses the placental barrier. Preclinical studies have not revealed any direct or indirect harmful effects of the drug on the course of pregnancy, embryonic/fetal development, labor, or postnatal development. Based on extensive clinical experience with the drug after the 28th week of pregnancy, no adverse effects on the fetus have been observed. However, the usual precautions regarding medication use during pregnancy should be observed. In particular, the use of Lazolvan® Strawberry-Cream Flavored Syrup is not recommended during the first trimester of pregnancy.
Breastfeeding. Ambroxol hydrochloride passes into breast milk. Lazolvan® Strawberry-Cream Flavored Syrup is not recommended for use during breastfeeding.
Fertility. Preclinical studies do not indicate any direct or indirect adverse effects on fertility.
Effect on reaction time when driving or operating machinery
There are no data on the effect on reaction time when driving or operating machinery. No studies have been conducted to assess the effect on reaction time when driving or operating machinery.
Dosage and Administration
Unless otherwise specified, the following dosage regimen is recommended for Lazolvan® Strawberry-Cream Flavored Syrup, 30 mg/5 mL:
Children under 2 years of age: 1.25 mL twice daily (equivalent to 15 mg of ambroxol hydrochloride per day).
Children aged 2 to 5 years: 1.25 mL 3 times daily (equivalent to 22.5 mg of ambroxol hydrochloride per day).
Children aged 6 to 12 years: 2.5 mL 2–3 times daily (equivalent to 30–45 mg of ambroxol hydrochloride per day).
Adults and children 12 years of age and older: the usual dose is 5 mL 3 times daily (equivalent to 90 mg of ambroxol hydrochloride per day) for the first 2–3 days, followed by 5 mL 2 times daily (equivalent to 60 mg of ambroxol hydrochloride per day).
If necessary, the therapeutic effect for adults and children 12 years of age and older may be enhanced by increasing the dose to 10 mL twice daily (equivalent to 120 mg of ambroxol hydrochloride per day).
Lazolvan® Strawberry-Cream Flavored Syrup, 30 mg/5 mL, may be taken with or without food. The dose of Lazolvan® Strawberry-Cream Flavored Syrup can be measured using the included measuring cap.
In general, there are no restrictions on the duration of use, but long-term therapy should be conducted under medical supervision.
Lazolvan® strawberry-cream flavored syrup, 30 mg/5 mL, should not be used for more than 4–5 days without consulting a doctor.
Lasolvan® Strawberry-Cream Flavored Syrup, 30 mg/5 mL, is suitable for use by patients with diabetes; 5 mL of syrup contains 1.2 g of carbohydrates.
Lasolvan® Strawberry-Cream Flavored Syrup, 30 mg/5 mL, does not contain alcohol.
Children
This medication may be used in pediatric practice. For children under 2 years of age, use only as directed by a doctor.
Overdose
To date, there have been no reports of specific symptoms of overdose. Symptoms reported in isolated cases of overdose and/or accidental medication ingestion correspond to the known side effects of Lazolvan® at recommended doses and require symptomatic treatment.
Side Effects
The following classification was used to assess the frequency of adverse events:
very common ≥1/10
common ≥1/100 – <1/10
uncommon ≥1/1,000 – <1/100
rare ≥1/10,000 – <1/1,000
very rare <1/10,000
Unknown: cannot be estimated from the available data
Immune system disorders and disorders of the skin and subcutaneous tissue:
Rare – hypersensitivity reactions;
Unknown – anaphylactic reactions, including anaphylactic shock, angioedema, and pruritus.
Skin and subcutaneous tissue disorders:
Rare – rash, hives;
unknown – serious skin adverse reactions (including erythema multiforme, Stevens-Johnson syndrome/toxic epidermal necrolysis, and acute generalized exanthematous pustulosis).
Nervous system:
common – dysgeusia (taste disturbance).
Gastrointestinal system:
common – nausea, decreased sensation in the mouth;
uncommon – vomiting, diarrhea, dyspepsia, abdominal pain, dry mouth;
Rare – dry throat;
very rarely – hypersalivation.
Respiratory, thoracic, and mediastinal disorders:
common – decreased sensation in the pharynx;
unknown – dyspnea (as a symptom of a hypersensitivity reaction).
General disorders:
uncommon – fever, mucosal reactions.
Reporting Suspected Adverse Reactions
Reporting suspected adverse reactions after a drug’s approval is an important procedure. This allows for ongoing monitoring of the benefit-risk profile of this drug. Healthcare professionals are asked to report all suspected adverse reactions to the State Expert Center of the Ministry of Health of Ukraine.
Shelf life
3 years.
Do not use the product after the expiration date indicated on the packaging.
Shelf life after first opening the vial: 6 months.
Storage Conditions
Store at a temperature not exceeding 25 °C in a place inaccessible to children.
Packaging
100 or 200 mL in a glass vial; 1 vial per package, complete with a plastic measuring cap, in a cardboard box.
Dispensing Category
Available without a prescription.
Similar products
Products from the same category











